In a study of 389 patients with non-metastatic HRPC treated with I-125 brachytherapy, Abigail Lauren Stockham, MD, and colleagues at Cleveland Clinic in Ohio found that after a median follow-up of 27 months, the five-year biochemical recurrence-free survival rate was 75.7% and the five-year distant metastasis-free survival rate was 93.1%. Nine patients (2.3%) died from their cancer. The study revealed no clinical or treatment factors that correlated with biochemical failure, including the use of androgen deprivation.
The study cohort had a median age of 70 years and a median initial PSA level of 11.3 ng/mL. Gleason scores of 8-10 accounted for 40% of cases. Concurrent androgen deprivation was used in 67% of men.
The symposium was co-sponsored by the American Society of Clinical Oncology, the American Society of Radiation Oncology, and the Society of Urologic Oncology.